Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel - 2Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- 3At UN climate conference, some activists and scientists want more talk on reforming agriculture
- 4The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- 5Triumph's 400 Range Has Just Changed In India, And Here's Why
- Pleasant Cycle Courses All over the Planet
- Burkina Faso forces killed twice as many civilians as jihadists, rights group says
- Terminal cancer diagnosis announced by JFK's granddaughter
- 2 bright planets light up April evenings — here's where and when to look
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- Hundreds show fascist salute at rally in Rome in annual ritual
- NASA will bring space station crew home early after medical issue
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
